{
  "id": "6414638c201352f04a000047",
  "type": "factoid",
  "question": "Cereblon (CRBN)  has been identified as the target for what type of drug?",
  "ideal_answer": "Immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide. IMiDs bind to CRBN and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33777938",
    "http://www.ncbi.nlm.nih.gov/pubmed/26990986",
    "http://www.ncbi.nlm.nih.gov/pubmed/26186254",
    "http://www.ncbi.nlm.nih.gov/pubmed/26002965",
    "http://www.ncbi.nlm.nih.gov/pubmed/34316334",
    "http://www.ncbi.nlm.nih.gov/pubmed/21207098",
    "http://www.ncbi.nlm.nih.gov/pubmed/32333926",
    "http://www.ncbi.nlm.nih.gov/pubmed/35831190",
    "http://www.ncbi.nlm.nih.gov/pubmed/24328678",
    "http://www.ncbi.nlm.nih.gov/pubmed/28978850",
    "http://www.ncbi.nlm.nih.gov/pubmed/29530986",
    "http://www.ncbi.nlm.nih.gov/pubmed/35045330",
    "http://www.ncbi.nlm.nih.gov/pubmed/23565715",
    "http://www.ncbi.nlm.nih.gov/pubmed/35780831",
    "http://www.ncbi.nlm.nih.gov/pubmed/26117057",
    "http://www.ncbi.nlm.nih.gov/pubmed/22966948",
    "http://www.ncbi.nlm.nih.gov/pubmed/27294876",
    "http://www.ncbi.nlm.nih.gov/pubmed/22552008",
    "http://www.ncbi.nlm.nih.gov/pubmed/31187860",
    "http://www.ncbi.nlm.nih.gov/pubmed/33938033",
    "http://www.ncbi.nlm.nih.gov/pubmed/36252444",
    "http://www.ncbi.nlm.nih.gov/pubmed/25626321",
    "http://www.ncbi.nlm.nih.gov/pubmed/34033753",
    "http://www.ncbi.nlm.nih.gov/pubmed/31202702"
  ],
  "snippets": [
    {
      "text": "Cereblon is a well-known target of thalidomide and its derivatives.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We have identified novel CRBN inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " It additionally modulates the anti-myeloma effect of the immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide. IMiDs bind to CRBN and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045330",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs\u00ae) lenalidomide (LEN) and pomalidomide (POM) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34316334",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (CRBN) as a primary direct target of this drug b",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31202702",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The molecular mechanism of action of IMiDs remained unclear for a long time until 2010 when the protein cereblon (CRBN) was identified as a primary direct target. IMiDs binds to CRBN and alters the substrate specificity of the CRBN E3 ubiquitin ligase complex, ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31187860",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results strongly suggest that increased BK channel activity is the pathological mechanism of intellectual disability in CRBN mutations.SIGNIFICANCE STATEMENTCereblon (CRBN), a well known target of the immunomodulatory drug thalidomide, was originally identified as a gene that causes human intellectual disability when mutated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29530986",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Cereblon (CRBN), a substrate receptor for the cullin-RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26990986",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our biophysical, biochemical and gene silencing studies show that CRBN is a proximate, therapeutically important molecular target of lenalidomide and pomalidomide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CRBN has been identified as a direct target for immunomodulatory drugs (IMiD) and plays a significant role in anti-proliferation, pro-apoptotic effects, anti-angiogenic activities, immunomodulatory activities and intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26117057",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thalidomide and its derivatives lenalidomide and\u00a0pomalidomide, known as immunomodulatory drugs, (IMiDs)\u00a0bind\u00a0directly to cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase, resulting in the rapid ubiquitination and degradation of the substrate protein.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33938033",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN) is a common primary target for IMiDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN), a substrate receptor of the CRL4 ubiquitin ligase complex, is the primary target by which IMiDs mediate anticancer and teratogenic effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27294876",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565715",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was identified as primary target of thalidomide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34033753",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical interest in the measurement of Cereblon (CRBN), the primary target of the IMiDs immunomodulatory drugs lenalidomide and pomalidomide, has been fueled by its essential requirement for antitumor or immunomodulatory activity of both drugs in multiple myeloma (MM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26186254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN), a substrate receptor for Cullin-ring E3 ubiquitin ligase (CRL), is a major target protein of immunomodulatory drugs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32333926",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN), a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex, is the target of the immunomodulatory drugs lenalidomide and pomalidomide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26002965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon was identified as a direct target of thalidomide by Prof. H. Handa, and this pioneering work triggered active research on IMiDs (immunomodulatory drugs), which include thalidomide-derivatives, such as lenalidomide and pomalidomide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25626321",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Cullin-RING ligase 4 E3 ubiquitin ligase component Cereblon (CRBN) is a well-established target for a class of small molecules termed immunomodulatory drugs (IMiDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35780831",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " We identified a thalidomide-binding protein, cereblon (CRBN), as a primary target for thalidomide teratogenicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21207098",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Although the direct target of thalidomide was largely debated until recently, our groups discovered cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase as a primary target of thalidomide in 2010.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35831190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Cereblon (CRBN) is a common primary target for IMiDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "d previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase c",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "dy recently identified cereblon (CRBN) as a primary target of thalidomide teratogenicity. Subsequently it was demonstrated that CRBN is also required ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22966948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to le",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565715",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(C",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328678",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328678",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cluding multiple myeloma. Cereblon (CRBN) is a common primary target for IMiDs. It works as a substrate receptor of CRL4. Accumulating evidence has sh",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ubiquitin ligase complex component. Cereblon is a well-known target of thalidomide and its derivatives. Cereblon is involved in multiple myeloma cell ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36252444",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Immunomodulatory drugs (IMiDs), Thalidomide, pomalidomide, lenalidomide"
}